nodes	percent_of_prediction	percent_of_DWPC	metapath
Ximelagatran—F2—Captopril—systemic scleroderma	0.819	0.934	CbGbCtD
Ximelagatran—F2—cardial valve—systemic scleroderma	0.0628	0.513	CbGeAlD
Ximelagatran—CYP2C9—Leflunomide—systemic scleroderma	0.0576	0.0657	CbGbCtD
Ximelagatran—CYP2C9—cardial valve—systemic scleroderma	0.025	0.204	CbGeAlD
Ximelagatran—F2—artery—systemic scleroderma	0.00943	0.077	CbGeAlD
Ximelagatran—F2—endothelium—systemic scleroderma	0.00796	0.065	CbGeAlD
Ximelagatran—F2—blood vessel—systemic scleroderma	0.00734	0.06	CbGeAlD
Ximelagatran—F2—connective tissue—systemic scleroderma	0.00377	0.0308	CbGeAlD
Ximelagatran—F2—digestive system—systemic scleroderma	0.00272	0.0222	CbGeAlD
Ximelagatran—F2—lung—systemic scleroderma	0.00227	0.0186	CbGeAlD
Ximelagatran—CYP2C9—digestive system—systemic scleroderma	0.00108	0.00885	CbGeAlD
Ximelagatran—F2—Platelet Aggregation (Plug Formation)—CSK—systemic scleroderma	6.15e-05	0.0871	CbGpPWpGaD
Ximelagatran—F2—Regulation of IGF Activity by IGFBP—MMP1—systemic scleroderma	4.56e-05	0.0645	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—CSF1—systemic scleroderma	4.39e-05	0.0622	CbGpPWpGaD
Ximelagatran—F2—Regulation of IGF Activity by IGFBP—MMP2—systemic scleroderma	3.53e-05	0.0499	CbGpPWpGaD
Ximelagatran—F2—IL1 and megakaryotyces in obesity—CCL2—systemic scleroderma	3.33e-05	0.0472	CbGpPWpGaD
Ximelagatran—F2—Cell surface interactions at the vascular wall—SELP—systemic scleroderma	3.29e-05	0.0466	CbGpPWpGaD
Ximelagatran—F2—Cell surface interactions at the vascular wall—ITGAM—systemic scleroderma	2.63e-05	0.0373	CbGpPWpGaD
Ximelagatran—F2—IL1 and megakaryotyces in obesity—IL1B—systemic scleroderma	2.53e-05	0.0358	CbGpPWpGaD
Ximelagatran—F2—IL1 and megakaryotyces in obesity—MMP9—systemic scleroderma	2.38e-05	0.0337	CbGpPWpGaD
Ximelagatran—F2—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	2.02e-05	0.0286	CbGpPWpGaD
Ximelagatran—F2—Syndecan-4-mediated signaling events—MMP9—systemic scleroderma	1.89e-05	0.0268	CbGpPWpGaD
Ximelagatran—F2—PAR1-mediated thrombin signaling events—NOS3—systemic scleroderma	1.86e-05	0.0264	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—CCL2—systemic scleroderma	1.82e-05	0.0258	CbGpPWpGaD
Ximelagatran—F2—Angiopoietin receptor Tie2-mediated signaling—MMP2—systemic scleroderma	1.76e-05	0.025	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	1.73e-05	0.0245	CbGpPWpGaD
Ximelagatran—F2—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	1.65e-05	0.0234	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	1.62e-05	0.0229	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—CCL2—systemic scleroderma	1.48e-05	0.021	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	1.47e-05	0.0208	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—IL1B—systemic scleroderma	1.38e-05	0.0196	CbGpPWpGaD
Ximelagatran—F2—Cell surface interactions at the vascular wall—MMP1—systemic scleroderma	1.32e-05	0.0187	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—CCL2—systemic scleroderma	1.18e-05	0.0167	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—IL1B—systemic scleroderma	1.12e-05	0.0159	CbGpPWpGaD
Ximelagatran—F2—G alpha (q) signalling events—EDN1—systemic scleroderma	9.43e-06	0.0134	CbGpPWpGaD
Ximelagatran—F2—Peptide ligand-binding receptors—EDN1—systemic scleroderma	9.31e-06	0.0132	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—IL1B—systemic scleroderma	8.94e-06	0.0127	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—SELP—systemic scleroderma	8.92e-06	0.0126	CbGpPWpGaD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	8.43e-06	0.0119	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—RHOB—systemic scleroderma	8.33e-06	0.0118	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—CSK—systemic scleroderma	7.59e-06	0.0107	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—ITGAM—systemic scleroderma	7.13e-06	0.0101	CbGpPWpGaD
Ximelagatran—F2—Peptide ligand-binding receptors—CCL2—systemic scleroderma	6.36e-06	0.00901	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	6.25e-06	0.00884	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—RHOB—systemic scleroderma	5.26e-06	0.00745	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—RHOB—systemic scleroderma	4.78e-06	0.00677	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—EDN1—systemic scleroderma	4.76e-06	0.00673	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—ACE—systemic scleroderma	4.38e-06	0.0062	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	4.27e-06	0.00605	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—SMAD7—systemic scleroderma	3.65e-06	0.00517	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—MMP1—systemic scleroderma	3.57e-06	0.00506	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.32e-06	0.00471	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—CCL2—systemic scleroderma	3.25e-06	0.0046	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—RHOB—systemic scleroderma	2.82e-06	0.004	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—MMP1—systemic scleroderma	2.81e-06	0.00398	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—EDN1—systemic scleroderma	2.69e-06	0.00381	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—HSPG2—systemic scleroderma	2.66e-06	0.00377	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—NOS3—systemic scleroderma	2.59e-06	0.00367	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—CSK—systemic scleroderma	2.57e-06	0.00364	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—EDN1—systemic scleroderma	2.44e-06	0.00346	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.32e-06	0.00329	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—CCL2—systemic scleroderma	2.29e-06	0.00324	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—MMP2—systemic scleroderma	2.18e-06	0.00308	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.76e-06	0.00249	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—TGFB1—systemic scleroderma	1.71e-06	0.00243	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—CCL2—systemic scleroderma	1.67e-06	0.00236	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—EDN1—systemic scleroderma	1.44e-06	0.00204	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—HSPG2—systemic scleroderma	1.03e-06	0.00146	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—CCL2—systemic scleroderma	9.86e-07	0.0014	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—NOS3—systemic scleroderma	8.78e-07	0.00124	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—CTGF—systemic scleroderma	7.84e-07	0.00111	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—MMP9—systemic scleroderma	7.05e-07	0.000998	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—TGFB1—systemic scleroderma	5.81e-07	0.000823	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—NOS3—systemic scleroderma	3.41e-07	0.000483	CbGpPWpGaD
